Literature DB >> 29791060

Implementing an innovated preservation technology: The American Society of Transplant Surgeons' (ASTS) Standards Committee White Paper on Ex Situ Liver Machine Perfusion.

Cristiano Quintini1, Paulo N Martins2, Shimul Shah3, Mary Killackey4, Alan Reed5, James Guarrera6, David A Axelrod7.   

Abstract

The pervasive shortage of deceased donor liver allografts contributes to significant waitlist mortality despite efforts to increase organ donation. Ex vivo liver perfusion appears to enhance preservation of donor organs, extending viability and potentially evaluating function in organs previously considered too high risk for transplant. These devices pose novel challenges for organ allocation, safety, training, and finances. This white paper describes the American Society of Transplant Surgeons' belief that organ preservation technology is a vital advance, but its use should not change fundamental aspects of organ allocation. Additional data elements need to be collected, made available for organ assessment by transplant professionals to allow determination of organ suitability in the case of reallocation and incorporated into risk adjustment methodology. Finally, further work is needed to determine the optimal strategy for management and oversight of perfused organs prior to transplantation.
© 2018 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  clinical research/practice; editorial/personal viewpoint; liver transplantation/hepatology; organ perfusion and preservation; organ procurement; organ procurement and allocation; organ procurement organization; risk assessment/risk stratification

Mesh:

Year:  2018        PMID: 29791060     DOI: 10.1111/ajt.14945

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  4 in total

1.  Lung transplantation after ex vivo lung perfusion versus static cold storage: An institutional cost analysis.

Authors:  Samantha E Halpern; Samuel J Kesseli; Sandra Au; Madison K Krischak; Danae G Olaso; Haley Smith; Greg Tipton; Ian R Jamieson; Andrew S Barbas; John C Haney; Jacob A Klapper; Matthew G Hartwig
Journal:  Am J Transplant       Date:  2021-09-02       Impact factor: 8.086

2.  Peritransplant VLA-4 blockade inhibits endogenous memory CD8 T cell infiltration into high-risk cardiac allografts and CTLA-4Ig resistant rejection.

Authors:  Shoichi Iida; Satoshi Miyairi; Charles A Su; Toyofumi Abe; Ryo Abe; Kazunari Tanabe; Nina Dvorina; William M Baldwin; Robert L Fairchild
Journal:  Am J Transplant       Date:  2018-11-26       Impact factor: 8.086

3.  Clinical transplantation using negative pressure ventilation ex situ lung perfusion with extended criteria donor lungs.

Authors:  Max T Buchko; Nasim Boroumand; Jeffrey C Cheng; Alim Hirji; Kieran Halloran; Darren H Freed; Jayan Nagendran
Journal:  Nat Commun       Date:  2020-11-13       Impact factor: 14.919

4.  Prospective, single-centre, randomised controlled trial to evaluate the efficacy and safety of ischaemia-free liver transplantation (IFLT) in the treatment of end-stage liver disease.

Authors:  Changjun Huang; Shanzhou Huang; Yunhua Tang; Qiang Zhao; Dongping Wang; Weiqiang Ju; Lu Yang; Jian Zhang; Linwei Wu; Maogen Chen; Zhiheng Zhang; Zebin Zhu; Linhe Wang; Caihui Zhu; Yixi Zhang; Chengjun Sun; Wei Xiong; Yuekun Shen; Xiaoxiang Chen; Yi Ma; Anbin Hu; Xiaofeng Zhu; Jian Rong; Changjie Cai; Zhiyong Guo; Xiaoshun He
Journal:  BMJ Open       Date:  2020-05-05       Impact factor: 2.692

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.